These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 21387286)

  • 1. E-cadherin expression on human carcinoma cell affects trastuzumab-mediated antibody-dependent cellular cytotoxicity through killer cell lectin-like receptor G1 on natural killer cells.
    Yamauchi C; Fujii S; Kimura T; Kuwata T; Wada N; Mukai H; Matsumoto N; Fukayama M; Ochiai A
    Int J Cancer; 2011 May; 128(9):2125-37. PubMed ID: 21387286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells.
    Reim F; Dombrowski Y; Ritter C; Buttmann M; Häusler S; Ossadnik M; Krockenberger M; Beier D; Beier CP; Dietl J; Becker JC; Hönig A; Wischhusen J
    Cancer Res; 2009 Oct; 69(20):8058-66. PubMed ID: 19826050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition.
    Di Modica M; Sfondrini L; Regondi V; Varchetta S; Oliviero B; Mariani G; Bianchi GV; Generali D; Balsari A; Triulzi T; Tagliabue E
    Oncotarget; 2016 Jan; 7(1):255-65. PubMed ID: 26595802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2.
    Varchetta S; Gibelli N; Oliviero B; Nardini E; Gennari R; Gatti G; Silva LS; Villani L; Tagliabue E; Ménard S; Costa A; Fagnoni FF
    Cancer Res; 2007 Dec; 67(24):11991-9. PubMed ID: 18089830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adipose cells promote resistance of breast cancer cells to trastuzumab-mediated antibody-dependent cellular cytotoxicity.
    Duong MN; Cleret A; Matera EL; Chettab K; Mathé D; Valsesia-Wittmann S; Clémenceau B; Dumontet C
    Breast Cancer Res; 2015 Apr; 17(1):57. PubMed ID: 25908175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status.
    Raab S; Steinbacher J; Schmiedel BJ; Kousis PC; Steinle A; Jung G; Grosse-Hovest L; Salih HR
    J Immunol; 2014 Oct; 193(8):4261-72. PubMed ID: 25217158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing.
    Kute TE; Savage L; Stehle JR; Kim-Shapiro JW; Blanks MJ; Wood J; Vaughn JP
    Cancer Immunol Immunother; 2009 Nov; 58(11):1887-96. PubMed ID: 19340424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
    Sliwkowski MX; Lofgren JA; Lewis GD; Hotaling TE; Fendly BM; Fox JA
    Semin Oncol; 1999 Aug; 26(4 Suppl 12):60-70. PubMed ID: 10482195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-associated E-cadherin mutations affect binding to the killer cell lectin-like receptor G1 in humans.
    Schwartzkopff S; Gründemann C; Schweier O; Rosshart S; Karjalainen KE; Becker KF; Pircher H
    J Immunol; 2007 Jul; 179(2):1022-9. PubMed ID: 17617594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab.
    Tokuyama H; Hagi T; Mattarollo SR; Morley J; Wang Q; So HF; Moriyasu F; Nieda M; Nicol AJ
    Int J Cancer; 2008 Jun; 122(11):2526-34. PubMed ID: 18307255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.
    Cooley S; Burns LJ; Repka T; Miller JS
    Exp Hematol; 1999 Oct; 27(10):1533-41. PubMed ID: 10517495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term preservation of antibody-dependent cellular cytotoxicity (ADCC) of natural killer cells amplified in vitro from the peripheral blood of breast cancer patients after chemotherapy.
    Clémenceau B; Gallot G; Vivien R; Gaschet J; Campone M; Vié H
    J Immunother; 2006; 29(1):53-60. PubMed ID: 16365600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Killer cell lectin-like receptor G1 binds three members of the classical cadherin family to inhibit NK cell cytotoxicity.
    Ito M; Maruyama T; Saito N; Koganei S; Yamamoto K; Matsumoto N
    J Exp Med; 2006 Feb; 203(2):289-95. PubMed ID: 16461340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel enhances antibody-dependent cell-mediated cytotoxicity of trastuzumab by rapid recruitment of natural killer cells in HER2-positive breast cancer.
    Miura D; Yoneyama K; Furuhata Y; Shimizu K
    J Nippon Med Sch; 2014; 81(4):211-20. PubMed ID: 25186575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy.
    Lu H; Yang Y; Gad E; Inatsuka C; Wenner CA; Disis ML; Standish LJ
    Clin Cancer Res; 2011 Nov; 17(21):6742-53. PubMed ID: 21918170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity.
    Tóth G; Szöőr Á; Simon L; Yarden Y; Szöllősi J; Vereb G
    MAbs; 2016 Oct; 8(7):1361-1370. PubMed ID: 27380003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo.
    Barok M; Tanner M; Köninki K; Isola J
    Breast Cancer Res; 2011 Apr; 13(2):R46. PubMed ID: 21510863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients.
    Suzuki E; Niwa R; Saji S; Muta M; Hirose M; Iida S; Shiotsu Y; Satoh M; Shitara K; Kondo M; Toi M
    Clin Cancer Res; 2007 Mar; 13(6):1875-82. PubMed ID: 17363544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction between HLA-G and NK cell receptor KIR2DL4 orchestrates HER2-positive breast cancer resistance to trastuzumab.
    Zheng G; Guo Z; Li W; Xi W; Zuo B; Zhang R; Wen W; Yang AG; Jia L
    Signal Transduct Target Ther; 2021 Jun; 6(1):236. PubMed ID: 34158475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
    Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.